Company intelligence / Profile preview
Velico
Beverly, Massachusetts, United Statesveli.co ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Velico’s FrontlineODP™ system received FDA Investigational Device Exemption approval in June 2021, Phase 1 escalating dose safety study started December 2022, with BARDA funding for clinical and commercial readiness; the product conducted initial clinical safety studies, aims to support rapid transfusion in pre-hospital and emergency/military settings[4][1].
- Therapeutic areas
- HematologyOther
- Modalities
- DeviceBiologicBlood product (plasma)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
American National Red Cross (blood center education program)BARDA (Biomedical Advanced Research and Development Authority, contract funding)Entegrion (past IP/license collaboration, now IP purchased back by Velico)
Beyond the preview
Go deeper on Velico.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Velico.